Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $24.25

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus rating of “Moderate Buy” by the ten research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $24.25.

XNCR has been the topic of several analyst reports. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. upped their price objective on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Truist Financial reduced their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in XNCR. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. acquired a new position in Xencor in the 2nd quarter valued at $79,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xencor in the 4th quarter valued at $81,000. iSAM Funds UK Ltd bought a new position in Xencor in the 2nd quarter worth $122,000. Finally, Prelude Capital Management LLC bought a new position in Xencor in the 3rd quarter worth $139,000.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $17.47 on Monday. The business has a 50 day simple moving average of $13.21 and a 200 day simple moving average of $12.79. Xencor has a 52 week low of $6.92 and a 52 week high of $18.69. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -7.63 and a beta of 0.86.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The business had revenue of $4.52 million for the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. Xencor’s revenue was down 86.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.66) EPS. On average, analysts predict that Xencor will post -3.88 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.